The compound you're referring to, **1-(ethan-1-ol)-2-methyl-3-hydroxypyridin-4-one**, is more commonly known as **deferiprone**. It's a **chelating agent** with significant importance in medical research. Here's why:
**What is Deferiprone?**
* **Structure:** Deferiprone is a small organic molecule containing a pyridin-4-one ring with a hydroxyl group, a methyl group, and an ethan-1-ol group attached.
* **Function:** It acts as a **chelating agent**, meaning it can bind to metal ions, particularly iron (Fe).
**Importance in Research:**
* **Iron Chelation in Medicine:** Deferiprone's ability to bind iron makes it valuable for treating iron overload disorders like:
* **Thalassemia:** A genetic disorder where the body produces abnormal hemoglobin, leading to iron buildup.
* **Hemochromatosis:** A condition where the body absorbs too much iron from the diet.
* **Transfusional Iron Overload:** Occurs in patients who receive frequent blood transfusions.
* **Other Potential Applications:** Deferiprone is being investigated for its potential in:
* **Cancer Treatment:** Some research suggests it may have anti-cancer effects, possibly by inhibiting the growth of cancer cells.
* **Neurodegenerative Diseases:** Deferiprone's ability to chelate iron has shown promise in preventing and treating neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Antimicrobial Activity:** Studies are ongoing to explore its potential as an antimicrobial agent.
**Current Status:**
* **FDA Approval:** Deferiprone is approved by the FDA for the treatment of iron overload in patients with thalassemia.
* **Ongoing Research:** Extensive research is ongoing to explore its potential in other medical applications and to better understand its mechanisms of action.
**Note:** Deferiprone is a prescription medication and should only be used under the guidance of a healthcare professional. It can have side effects, and it's essential to follow the doctor's instructions.
1-(ethan-1-ol)-2-methyl-3-hydroxypyridin-4-one: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 94414 |
| CHEMBL ID | 79782 |
| SCHEMBL ID | 4394165 |
| MeSH ID | M0258008 |
| Synonym |
|---|
| CHEMBL79782 |
| NCI60_003174 |
| nsc-353638 |
| nsc353638 |
| 30652-21-2 |
| 4(1h)-pyridinone, 3-hydroxy-1-(2-hydroxyethyl)-2-methyl- |
| 1-(ethan-1-ol)-2-methyl-3-hydroxypyridin-4-one |
| brn 1454566 |
| 3-hydroxy-1-(2-hydroxyethyl)-2-methyl-4(1h)-pyridinone |
| cp40 (chelating agent) |
| 3-hydroxy-1-(2-hydroxyethyl)-2-methylpyridin-4(1h)-one |
| 3-hydroxy-1-(2-hydroxyethyl)-2-methylpyridin-4-one |
| AKOS006276802 |
| cp40 compound |
| nsc 353638 |
| 3-hydroxy-1(2'-hydroxyethyl)-2-methylpyrid-4-one |
| ZJDRWNJIMXVJQG-UHFFFAOYSA-N |
| 1-(2'-hydroxyethyl)-3-hydroxy-2-methyl-4-pyridinone |
| SCHEMBL4394165 |
| STL421815 |
| DTXSID70184700 |
| VS-13756 |
| 3-hydroxy-1-(2-hydroxyethyl)-2-methyl-1,4-dihydropyridin-4-one |
| BBL036878 |
| 4(1h)-pyridone, 3-hydroxy-1-(2-hydroxyethyl)-2-methyl- |
| cp-40 (chelating agent) |
| T5FE5EU7U5 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " More frequent dosing and/or a longer duration of HP treatment might produce greater reversal of the Al-induced toxicity and perhaps reveal more adverse effects than seen in this study." | ( Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity. Dickey, KM; Fredenburg, AM; Hong, CB; Meurer, KA; Skinner, TL; Yokel, RA, 1997) | 0.3 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Their pharmacokinetics were determined in rats to establish dosing parameters for microdialysis studies of BBB permeation." | ( The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Allen, DD; Fredenburg, AM; Sethi, RK; Yokel, RA, 1996) | 0.29 |
| " More frequent dosing and/or a longer duration of HP treatment might produce greater reversal of the Al-induced toxicity and perhaps reveal more adverse effects than seen in this study." | ( Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity. Dickey, KM; Fredenburg, AM; Hong, CB; Meurer, KA; Skinner, TL; Yokel, RA, 1997) | 0.3 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID210782 | Percentage of removal of iron from iron-protein-transferrin | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. |
| AID26251 | Partition coefficient (logD7.4) for iron(III) complexes | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID26827 | Compound was tested for equilibrium constants (pKa2) of the (carboxyalkyl) pyridinone corresponds to the carboxylic function potentiometrically | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID26619 | Compound was tested for equilibrium constants (pKa1) potentiometrically | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID193977 | The amount of iron-binding when iron chelator administered in the bile duct-cannulated rats. | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID26260 | Partition coefficient (logD7.4) | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID72978 | Percentage of removal of iron from iron-protein-ferritin | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. |
| AID229913 | Spectrophotometric selectivity ratio for pKa2 and pKa3 | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID26828 | Compound was tested for equilibrium constants (pKa2) of the (carboxyalkyl) pyridinone corresponds to the carboxylic function spectrophotometrically.. | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID26620 | Compound was tested for equilibrium constants (pKa1) spectrophotometrically. | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID231251 | Potentiometric selectivity ratio for pKa2 and pKa3 | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID193973 | The amount iron excretion in the bile duct-cannulated rats when iron chelator administered subcutaneously at dose 122 mg/kg | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID193841 | The amount iron excretion in the bile duct-cannulated rats when iron chelator administered orally at dose 122 mg/kg | 1998 | Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18 | Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. |
| AID28984 | Partition coefficient (logD7.4) | 1993 | Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17 | Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (18.75%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (81.25%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||